首页 > 市场调查报告书 > 製药

癌症

多发性骨髓瘤市场规模、份额和成长分析（按药物类别、治疗方法、通路和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1899391

多发性骨髓瘤市场规模、份额和成长分析（按药物类别、治疗方法、通路和地区划分）－2026-2033年产业预测

Multiple Myeloma Market Size, Share, and Growth Analysis, By Drug Class (Proteasome Inhibitors, Immunomodulatory Drugs), By Therapy (Immunotherapy, Chemotherapy), By Distribution channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，多发性骨髓瘤市场规模将达到 291.2 亿美元，到 2025 年将成长至 335.2 亿美元，到 2033 年将成长至 1032.5 亿美元，在预测期（2026-2033 年）内复合年增长率为 15.1%。

多发性骨髓瘤发生率的上升以及肿瘤研究投入的增加预计将推动市场成长。癌症治疗领域的创新，特别是CAR-T细胞疗法、单株抗体和免疫查核点抑制剂的日益普及，将使业内相关人员受益。对治疗方法和诊断研发的大量投入，以及对个人化医疗日益增长的关注，将为该领域的公司带来新的机会。加强提高大众对多发性骨髓瘤的认知度并促进早期诊断，将进一步扩大医疗服务提供者的市场。然而，高昂的治疗费用、潜在的副作用、认知不足以及抗药性的出现等挑战可能会限制市场的长期前景。

全球多发性骨髓瘤市场按药物类别、治疗方法、通路和地区进行细分。依药物类别划分，市场分为蛋白酶体抑制剂、免疫调节药物、单株抗体和类固醇。依治疗方法划分，市场分为免疫疗法、化疗、放射线治疗和干细胞移植。依通路划分，市场分为医院、零售药局和线上药局。按地区划分，市场分为北美、欧洲、亚太、中东和非洲以及拉丁美洲。

多发性骨髓瘤市场成长要素

全球人口老化预计将显着增加对多发性骨髓瘤治疗的需求，并成为市场发展的关键驱动因素。研究表明，老年人罹患多发性骨髓瘤的风险更高，这正在影响市场的扩张。随着该疾病盛行率老龄化增长而增加，对有效治疗方法和管理方案的需求预计将推动市场成长。这种人口结构变化表明，迫切需要改进治疗方法和资源，以应对老年人中多发性骨髓瘤面临的独特挑战。

多发性骨髓瘤市场限制因素

多发性骨髓瘤的治疗方法主要集中于化疗、免疫疗法和干细胞移植，但这些治疗方法都伴随着显着的副作用，包括神经病变、感染疾病和胃肠道併发症。这些严重的副作用可能会使患者放弃治疗，进而抑制多发性骨髓瘤治疗方法市场的需求。潜在患者在权衡治疗获益与潜在的严重副作用时，会降低现有治疗方法的整体接受度，这对多发性骨髓瘤治疗的发展构成重大挑战。这一限制凸显了该领域对更安全、耐受性更好的治疗方案的迫切需求。

多发性骨髓瘤市场趋势

多发性骨髓瘤市场正加速向精准医疗转型，反映出患者对个人化治疗方案的认知和需求日益增强。这一趋势使医疗服务提供者能够根据个别基因谱和生物标记分析客製化治疗方法，从而显着提高疗效并最大限度地减少副作用。透过采用精准医疗方法，企业可以改善患者的治疗效果和生活质量，从而提升消费者忠诚度和偏好度。随着对标靶治疗的关注度不断提高，多发性骨髓瘤领域的相关人员已做好充分准备，在竞争激烈的市场环境中创新并打造差异化的价值主张，以满足患者不断变化的需求。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

Bristol-Myers Squibb Company（US）
Amgen Inc.（US）
Johnson & Johnson（Janssen Pharmaceuticals）（US）
Novartis AG（Switzerland）
Sanofi（France）
Takeda Pharmaceutical Company Limited（Japan）
Pfizer Inc.（US）
Celgene Corporation（Bristol-Myers Squibb Company）（US）
AbbVie Inc.（US）
Genentech, Inc.（F. Hoffmann-La Roche Ltd）（US）
Karyopharm Therapeutics（US）
Teva Pharmaceutical Industries Ltd.（Israel）
ONO Pharmaceutical Co., Ltd.（Japan）
Merck & Co., Inc.（US）
Eli Lilly and Company（US）
GlaxoSmithKline plc（UK）
Bayer AG（Germany）
Takeda Oncology（Millennium Pharmaceuticals）（Japan）
Oncopeptides AB（Sweden）
Bluebird Bio, Inc.（US）

简介目录

Product Code: SQMIG35I2293

Multiple Myeloma Market size was valued at USD 29.12 Billion in 2024 and is poised to grow from USD 33.52 Billion in 2025 to USD 103.25 Billion by 2033, growing at a CAGR of 15.1% during the forecast period (2026-2033).

The increasing prevalence of multiple myeloma and heightened investment in oncology research are set to drive market growth. Innovations in cancer therapies, particularly the rising adoption of CAR-T cell therapy, monoclonal antibodies, and immune checkpoint inhibitors, will benefit industry players. Significant investments in the research and development of treatments and diagnostics, along with the escalating emphasis on personalized medicine, present new opportunities for companies in this sector. Increased initiatives to raise awareness of multiple myeloma and efforts to promote early diagnosis will further expand the market for providers. However, high treatment costs, the potential for adverse effects, lack of awareness, and the emergence of treatment resistance pose challenges that may restrict the positive market outlook over the long term.

Top-down and bottom-up approaches were used to estimate and validate the size of the Multiple Myeloma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Multiple Myeloma Market Segments Analysis

Global Multiple Myeloma Market is segmented on the drug class, therapy, distribution channel, and region. By drug class, market is segmented into Proteasome Inhibitors, Immunomodulatory Drugs,Monoclonal Antibodies, and Steroids. By therapy, market is segmented into immunotherapy, chemotherapy, radiation therapy, and stem cell transplant. By distribution channel, market is segmented into hospital, retail, and online pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Multiple Myeloma Market

The growing global population of older individuals is poised to significantly elevate the demand for multiple myeloma treatments, acting as a crucial driver for the market. Research indicates that aging adults are at a higher risk of developing multiple myeloma, consequently influencing the expansion of the market. As the prevalence of this condition rises with age, the need for effective therapies and management solutions is expected to increase, thereby propelling market growth. This demographic shift underscores the urgency for advancements in treatments and resources dedicated to addressing the unique challenges presented by multiple myeloma in older populations.

Restraints in the Multiple Myeloma Market

The treatment landscape for multiple myeloma predominantly features chemotherapy, immunotherapy, and stem cell transplants; however, these approaches come with significant risks of adverse effects, including neuropathy, infections, and gastrointestinal complications. Such severe side effects can discourage patients from pursuing treatment options, ultimately hindering the demand for therapies within the multiple myeloma market. As potential patients weigh the benefits against the potential for debilitating repercussions, the overall acceptance of available treatment modalities may diminish, posing a substantial challenge to the growth and advancement of multiple myeloma therapies. This restraint highlights the need for safer, more tolerable treatment alternatives in this field.

Market Trends of the Multiple Myeloma Market

The market for multiple myeloma is increasingly shifting towards personalized medicine, reflecting a growing awareness and demand among patients for tailored treatment options. This trend allows healthcare providers to customize therapies based on individual genetic profiles and biomarker analysis, significantly enhancing treatment efficacy while minimizing adverse effects. By adopting a personalized medicine approach, companies can improve patient outcomes and quality of life, fostering loyalty and preference among consumers. As the emphasis on targeted therapies continues to rise, stakeholders within the multiple myeloma sector are positioned to innovate and differentiate their offerings to meet the evolving needs of patients in a competitive landscape.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree Of Competition
Top Investment Pockets
Ecosystem Of the Market
Value Chain Analysis
Raw Material Analysis
Pricing Analysis
Consumer Behaviour Analysis
PESTLE Analysis

Multiple Myeloma Market, By Drug Class

Market Overview
Proteasome Inhibitors
Immunomodulatory Drugs
Monoclonal Antibodies
Steroids

Multiple Myeloma Market, By Therapy

Market Overview
Immunotherapy
Chemotherapy
Radiation Therapy
Stem Cell Transplant

Multiple Myeloma Market, By Distribution Channel

Market Overview
Hospital
Retail
Online Pharmacies

Multiple Myeloma Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (Janssen Pharmaceuticals) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (Bristol-Myers Squibb Company) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech, Inc. (F. Hoffmann-La Roche Ltd) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Karyopharm Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ONO Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Oncology (Millennium Pharmaceuticals) (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oncopeptides AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bluebird Bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments